Cipla recently announced the launch of a novel Synchrobreathe inhaler designed to effectively manage Obstructive Airway Disease (OAD). Synchrobreathe is an innovation in managing respiratory disease. Approximately 90% doctors in India reported prescribing inhaler devices to at least 40% of their asthma and COPD patients in the first clinic visit. Educating patients on the benefits of inhalation therapy and the correct inhaler technique can help increase the acceptance, adherence and correct usage of inhalers, which can result in better disease control.
In Delhi, the chronic respiratory disease is the leading cause of death in the 15-39 year age group and the third leading cause of death in the 40-69 year age group.
Also, COPD has moved from the 13th leading cause of death and disability in 1990 to the third leading cause in 2016. This shows the growing burden of respiratory disease and the burning need to control it.